Let's stand up to COVID-19

Major scientific breakthrough to treat COVID-19

January 27, 2021

On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial.

The COLCORONA study manuscript is now available in the public domain.

READ THE MANUSCRIPT

ANSWERS TO FREQUENTLY ASKED QUESTIONS

ColCorona_HeaderImg_001.jpg

Colcorona is a home-based clinical trial that determines whether short-term treatment with an existing medication reduces the risk of mortality and lung complications related to COVID-19.

It is a randomized, placebo-controlled study. It is double-blind - which means neither doctor nor patient will know whether you are taking the trial medication or a placebo.

icon_checkmark.png

United States: New York City Tri-State area, San Francisco, Los Angeles, Bakersfield, Downey, Miami, Jacksonville, Houston, Dallas, Phoenix, Yuma, Rochester, Tupelo, Greenville, Chapel Hill, Little Rock 

icon_checkmark.png

Canada: Quebec, Ontario, British-Columbia

icon_checkmark.png

Spain: Madrid

icon_checkmark.png

South Africa: Cape Town

icon_checkmark.png

Brazil: San Paolo

icon_checkmark.png

Greece: Athens, Kozani, Alexandroupoli, Elefsina, Patras

KEY TRIAL REQUIREMENTS

You must have been diagnosed with and currently have COVID-19

icon_checkmark.png

You must be 40 years old or over

icon_checkmark.png

Trial lasts 30 days from home

icon_checkmark.png

Daily intake of study medication or placebo

icon_checkmark.png

You must not be in hospital due to COVID-19

icon_checkmark.png

You must not be pregnant or breastfeeding

icon_checkmark.png
 

SPONSORS

This clinical trial is supported by

logo-icm_EN.jpg
logo-quebec_EN.jpg
MHICC_logo_en_S.jpg
ici-NYU-langone.png
logo_universite-montreal.png
logo_omnimed.png
logo-pharma science.png
logo-dacima.jpg
sponsor_CGI_.jpg
logo-chu quebec.jpg
logo_Telus.png
FJRSD-logo-EN.png